Navigating the IAFS-IV Postponement: Sovereign Public Health Law and Contractual Resilience for Indian Enterprises in Africa
Cross-Border Health Governance and the International Health Regulations
On 21 May 2026, the Ministry of External Affairs and the African Union Commission issued a joint press release deferring the Fourth India–Africa Forum Summit (IAFS-IV), which had been scheduled for New Delhi from 28–31 May. The decision, taken after consultations between the Government of India, the AU Chairperson, and the AU Commission, cited the "evolving public health situation in parts of Africa", a reference to the Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo and Uganda, which the World Health Organization had already declared a Public Health Emergency of International Concern on 17th May.
This is not the first time an Ebola outbreak has disrupted the India–Africa diplomatic calendar. The third edition of the summit, planned for 2014, was similarly deferred by a year due to the West African Ebola crisis. History has repeated itself, but this time, the legal and commercial implications are far more complex.
For Indian enterprises operating across the African continent, the postponement is not merely a diplomatic reschedule. It signals the urgency of building contractual resilience around sovereign public health disruptions. Unlike the 2014–15 context, Indian businesses today maintain deeper operational footprints in Africa, from pharmaceutical supply chains and medical technology deployments to infrastructure and digital public infrastructure projects. The legal frameworks governing these operations must now account for a reality in which public health emergencies are not exceptional events but recurring structural risks.
Cross-Border Health Governance and the International Health Regulations
The WHO declaration of a PHEIC under the International Health Regulations (2005) triggers a series of obligations for State Parties, including India and all African Union member states. The IHR amendments adopted in 2024 introduced significant revisions to notification timelines, core capacity requirements, and access to health products during emergencies. These amendments are now entering into force, creating a new compliance baseline for cross-border health governance.
The Africa Centres for Disease Control and Prevention (Africa CDC) has emerged as the continental coordinating authority for outbreak response. In the joint press release, India explicitly affirmed its readiness to contribute to Africa CDC-led efforts; reinforcing the institutional centrality of the Africa CDC in managing cross-border health crises. For Indian enterprises, this has direct operational consequences: Africa CDC travel advisories, port health restrictions, and border screening protocols now function as de facto regulatory barriers that can halt supply chains, delay personnel deployments, and trigger contractual default scenarios.
Businesses must monitor Africa CDC compliance frameworks not as optional public health guidance but as enforceable operational constraints. The Africa CDC Data Sharing Agreement, endorsed by the AU Assembly in early 2026, and the Continental Health Data Governance Framework currently under development, further complicate cross-border data flows for health-related enterprises, particularly those in telemedicine, diagnostics, and digital health infrastructure.
Force Majeure and Material Adverse Change in Cross-Border Contracts
The IAFS-IV postponement illustrates precisely the type of sovereign public health event that renders contractual performance impossible, or at least materially different from what the parties contemplated. For Indian enterprises with African operations, the critical legal question is whether existing contracts adequately address such disruptions.
Under Indian contract law, force majeure clauses excuse performance when events beyond the reasonable control of the parties render contractual obligations impossible. Section 56 of the Indian Contract Act, 1872, the doctrine of frustration, operates as a statutory backstop where contracts lack explicit force majeure provisions. However, Indian courts have historically interpreted force majeure clauses narrowly. The Hon'ble Supreme Court in Energy Watchdog v. Central Electricity Regulatory Commission (2017) emphasized that the event must be unforeseeable, that reasonable mitigation efforts must have been exhausted, and that performance must be actually impossible, not merely economically burdensome.
The Bundibugyo outbreak and the resulting summit postponement present a textbook force majeure scenario: a sovereign health emergency declared under international law, triggering border restrictions and operational halts that no contracting party could have prevented. Yet many Indian-African commercial agreements still rely on boilerplate force majeure language that may not explicitly enumerate "public health emergency," "PHEIC declaration," or "Africa CDC travel restriction" as qualifying events.
Material adverse change (MAC) clauses present additional complexity. Unlike force majeure provisions, which typically suspend performance, MAC clauses allocate risk between signing and closing, particularly in M&A transactions and long-term supply agreements. Indian courts have set a high threshold for MAC enforcement. In Gujarat Urja Vikas Nigam Ltd. v. Solar Semiconductor Power Company (2017), the Hon'ble Supreme Court held that policy changes affecting profitability did not constitute a MAC unless explicitly drafted into the agreement. Similarly, in Halliburton Offshore Services Inc. v. Vedanta Ltd. (2020), the Delhi High Court ruled that the COVID-19 pandemic, despite being unforeseen, did not automatically frustrate a contract merely because performance had become more difficult.
The lesson for Indian enterprises is straightforward: generic force majeure and MAC language is insufficient. Contracts must specifically enumerate public health emergencies, WHO PHEIC declarations, Africa CDC restrictions, and localized travel bans as qualifying events. They must also define the evidentiary requirements for invoking these provisions, including the types of official documentation that satisfy the notification burden. For a comparative framework on managing cross-border commercial risks under modern bilateral treaties, enterprises can consult our recent compliance guide for Indian exporters.
Supply Chain Insurance and Localised Public Health Restrictions
Standard commercial insurance policies rarely cover losses arising from public health emergencies. Indian enterprises operating in Africa must evaluate whether their existing coverage includes business interruption triggered by epidemic disease, border closures, or mandatory quarantine protocols. The ICC Force Majeure Clause 2020, which expressly references pandemics, quarantines, and health emergencies, has established a drafting standard for international contracts, but insurance markets have been slower to develop corresponding products.
Parametric insurance products, which pay out upon the occurrence of a predefined trigger event, such as a WHO PHEIC declaration or an Africa CDC public health emergency classification, offer one viable model. These instruments reduce the evidentiary burden on policyholders and accelerate recovery timelines, which is critical for supply chains operating on thin margins across African markets.
Indian pharmaceutical exporters, in particular, should review their cargo and transit insurance for exclusions related to epidemic disease. The 2024 IHR amendments introduced new obligations for State Parties regarding access to health products during emergencies, including prohibitions on export restrictions that are not scientifically justified. These provisions create both opportunities and compliance obligations for Indian generic drug manufacturers supplying African markets.
Pharmaceutical Technology Transfer and Regulatory Alignment
India's pharmaceutical sector, often described as the "pharmacy of the world", supplies a substantial share of Africa's generic medicines. The CDSCO's recent regulatory reforms, including the relaxation of export NoC requirements for non-SRA countries and the streamlining of IND approvals, are designed to accelerate this trade. However, cross-border pharmaceutical technology transfer involves navigating multiple regulatory layers: CDSCO export approvals, WHO-GMP certification, and the registration requirements of each African destination country.
The AfCFTA Protocol on Intellectual Property and the African Medicines Regulatory Harmonization initiative are gradually creating continental standards for pharmaceutical registration. Indian enterprises must align their technology transfer protocols with these evolving frameworks, particularly the African Union's target of manufacturing 60 percent of essential medical products on the continent by 2040, which implies a shift from pure export models to local manufacturing partnerships and licensed production arrangements.
These technology transfer arrangements must include explicit provisions addressing public health emergency scenarios: who bears the cost of regulatory re-registration when emergency use authorizations are invoked; how quality assurance obligations are allocated when supply chains are disrupted; and how intellectual property licensed for emergency production interacts with existing territorial restrictions.
India's generic drug frameworks, built on the Patents Act, 1970 and the subsequent TRIPS-compliant amendments, offer established pathways for affordable medicine exports. However, the integration of these frameworks with African regulatory bodies requires careful navigation. The African Medicines Agency, headquartered in Kigali, is gradually assuming a centralized role in continental drug approval. Indian manufacturers must ensure that their dossiers, bioequivalence data, and pharmacovigilance reporting meet the AMA's emerging standards, particularly for products destined for emergency stockpiles or outbreak response.
Practical Steps for Indian Enterprises
The postponement of IAFS-IV should prompt a systematic review of contractual frameworks across three operational dimensions. First, enterprises must audit all existing agreements with African counterparties to identify gaps in force majeure and MAC coverage. Clauses drafted before 2020 are particularly likely to lack explicit pandemic and public health emergency language. Second, businesses must revise their insurance portfolios to include parametric coverage tied to WHO and Africa CDC emergency declarations. Third, pharmaceutical and med-tech companies must verify that their regulatory dossiers are aligned with the African Medicines Agency's emerging requirements and that their technology transfer agreements anticipate emergency use scenarios.
These measures are not merely defensive. Enterprises that demonstrate contractual resilience and regulatory readiness during public health emergencies position themselves as preferred partners when donor-funded health procurement resumes and when bilateral initiatives like the IAFS-IV development agenda are reactivated.
Building Resilience into India–Africa Operations
The IAFS-IV postponement is a reminder that public health governance and commercial law are inseparable in cross-border operations. Indian enterprises cannot treat Ebola outbreaks, PHEIC declarations, or Africa CDC restrictions as externalities. They must be integrated into contract drafting, insurance planning, and compliance frameworks from the outset.
The summit will be rescheduled. The bilateral trade targets — projected to surpass USD 100 billion, remain achievable. But achieving them requires a robust cross-border investment architecture that acknowledges the reality of recurring public health crises in the region. Analysis from the Indo-AU Desk emphasizes that force majeure clauses must enumerate specific health-related triggers. MAC provisions must quantify the materiality threshold for outbreak-related disruptions. Supply chain insurance must cover PHEIC-triggered business interruption. And pharmaceutical technology transfers must anticipate emergency use scenarios.
The enterprises that build these safeguards now will not merely survive the next public health emergency. They will operate with a competitive advantage, the confidence that their contractual frameworks are aligned with the institutional reality of how India and Africa manage cross-border health crises together.
Beyond the complex architecture of cross-border contracts and regulatory compliance, our thoughts remain with the communities and frontline health workers currently navigating the immediate challenges of this outbreak. The enduring strength of the India-Africa partnership has historically been forged not merely through commerce, but through shared resilience and mutual support during times of crisis. As both regions step forward to meet this public health challenge, we remain profoundly optimistic that this pause will ultimately pave the way for a safer, more integrated, and deeply cooperative global framework.